Citius Oncology Stock Alpha and Beta Analysis
| CTOR Stock | 1.09 0.02 1.87% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Citius Oncology. It also helps investors analyze the systematic and unsystematic risks associated with investing in Citius Oncology over a specified time horizon. Remember, high Citius Oncology's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Citius Oncology's market risk premium analysis include:
Beta 0.53 | Alpha (0.65) | Risk 6.57 | Sharpe Ratio (0.08) | Expected Return (0.52) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Citius Oncology Backtesting, Citius Oncology Valuation, Citius Oncology Correlation, Citius Oncology Hype Analysis, Citius Oncology Volatility, Citius Oncology History and analyze Citius Oncology Performance. Citius Oncology Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Citius Oncology market risk premium is the additional return an investor will receive from holding Citius Oncology long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Citius Oncology. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Citius Oncology's performance over market.| α | -0.65 | β | 0.53 |
Citius Oncology expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Citius Oncology's Buy-and-hold return. Our buy-and-hold chart shows how Citius Oncology performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Citius Oncology Market Price Analysis
Market price analysis indicators help investors to evaluate how Citius Oncology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Citius Oncology shares will generate the highest return on investment. By understating and applying Citius Oncology stock market price indicators, traders can identify Citius Oncology position entry and exit signals to maximize returns.
Citius Oncology Return and Market Media
The median price of Citius Oncology for the period between Fri, Oct 17, 2025 and Thu, Jan 15, 2026 is 1.26 with a coefficient of variation of 19.53. The daily time series for the period is distributed with a sample standard deviation of 0.26, arithmetic mean of 1.36, and mean deviation of 0.23. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Will Citius Oncology Inc. stock keep outperforming rivals - Weekly Trend Recap Real-Time Stock Entry Alerts - newser.com | 11/13/2025 |
2 | Citius Oncology to Advance Commercial Launch of LYMPHIR with Verix AI Integration | 11/21/2025 |
3 | CTOR - Citius Oncology, Inc. Latest Stock News Market Updates - Stock Titan | 12/02/2025 |
4 | Citius Oncology added to the Russell Microcap Index | 12/09/2025 |
5 | Citius Oncology Posts Quarterly Earnings Results | 12/23/2025 |
6 | Earnings Miss Will Citius Oncology Inc stock sustain high P E ratios - July 2025 Institutional Verified Technical Signals - moha.gov.vn | 12/31/2025 |
7 | Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - GuruFocus | 01/07/2026 |
8 | Citius Oncology, Inc. Is Breakeven Near | 01/13/2026 |
About Citius Oncology Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Citius or other stocks. Alpha measures the amount that position in Citius Oncology has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Citius Oncology Investors Sentiment
The influence of Citius Oncology's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Citius. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Citius Oncology's public news can be used to forecast risks associated with an investment in Citius. The trend in average sentiment can be used to explain how an investor holding Citius can time the market purely based on public headlines and social activities around Citius Oncology. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Citius Oncology's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Citius Oncology's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Citius Oncology's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Citius Oncology.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Citius Oncology in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Citius Oncology's short interest history, or implied volatility extrapolated from Citius Oncology options trading.
Build Portfolio with Citius Oncology
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Citius Stock Analysis
When running Citius Oncology's price analysis, check to measure Citius Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology is operating at the current time. Most of Citius Oncology's value examination focuses on studying past and present price action to predict the probability of Citius Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology's price. Additionally, you may evaluate how the addition of Citius Oncology to your portfolios can decrease your overall portfolio volatility.